We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Zentalis Pharmaceuticals Inc
2 own
3 watching
Current Price
$0
$0.39
(1.6%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,467.04M
52-Week High
32.34
52-Week Low
15.55
Average Volume
1.93M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,467.04M52-Week High32.3452-Week Low15.55Average Volume1.93MDividend Yield--P/E Ratio--What does the Zentalis Pharmaceuticals Inc do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company s other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Read More
How much money does Zentalis Pharmaceuticals Inc make?
News & Events about Zentalis Pharmaceuticals Inc.
Globe Newswire
1month ago
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib Company also announces collaborations with Foundation Medicine and Roche ...
Globe Newswire
1month ago
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy combination study, including data on CCNE1 amplification and / or Cyclin E1 expression, in the first...
Business Wire
4 months ago
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (Zentalis or the Company). The investigations concern whether certain of the Zentalis officers and directors breached their fiduciary duties to...
Globe Newswire
5 months ago
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders. The investigation concerns potential ...
Zolmax
6 months ago
Zentalis Pharmaceuticals (NASDAQ:ZNTL Get Rating) had its price target reduced by Wells Fargo & Company from $52.00 to $46.00 in a research note released on Monday, The Fly reports. A number of other research firms have also weighed in on ZNTL. HC Wainwright reduced their price objective on shares ...
Frequently Asked Questions
Frequently Asked Questions
What is Zentalis Pharmaceuticals Inc share price today?
Can Indians buy Zentalis Pharmaceuticals Inc shares?
How can I buy Zentalis Pharmaceuticals Inc shares from India?
Can Fractional shares of Zentalis Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Zentalis Pharmaceuticals Inc stocks?
What is today’s traded volume of Zentalis Pharmaceuticals Inc?
What is today’s market capitalisation of Zentalis Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Zentalis Pharmaceuticals Inc?
What percentage is Zentalis Pharmaceuticals Inc down from its 52-Week High?
What percentage is Zentalis Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$0
$0.39
(1.6%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.